Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Stock Chart & Stats
$102.79
-$0.34(-2.31%)
At close: 4:00 PM EST
$102.79
-$0.34(-2.31%)
Day’s Range― - ―
52-Week Range$11.17 - $101.94
Previous CloseN/A
Volume11.83K
Average Volume (3M)202.82K
Market Cap
$1.11B
Enterprise Value$646.07M
Total Cash (Recent Filing)$63.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Apr 06, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding11,836,490
10 Day Avg. Volume265,123
30 Day Avg. Volume202,822
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-2.46
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-33.81
Forecast
1Y Price Target
$132.55Price Target Upside28.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market OpportunityPalvella will be pursuing the development of QTORIN pitavastatin in disseminated superficial actinic porokeratosis (DSAP), a rare dermatological disease with no FDA-approved therapies, presenting a sizeable market opportunity.
Pipeline ExpansionExpanding the QTORIN platform beyond Rapamycin to include a statin provides evidence of the breadth and scalability of the platform, in addition to the platform's versatility for future product candidates.
Product DevelopmentPalvella unveiled its first non-rapamycin QTORIN platform product, which is QTORIN pitavastatin, an FDA-approved statin that acts as an inhibitor of the mevalonate pathway.
Bears Say
Biology RiskThere is more biology risk with an mTOR inhibitor in CVMs due to the disease being driven by mutations in both TIE2 and PIK3CA.
Financial PerformanceA net loss of approximately $11.3 million was reported for the third quarter.
Short InterestShort Interest (% Float) 17.4%.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $11.17 and its highest was $101.94 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $1.11B.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 127 days.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on Nov 11, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.838 by -$0.192.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 11,836,490 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.838. Following the earnings report the stock price went down -3.039%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$132.55 (28.95% Upside)
$132.55 (28.95% Upside)
Hedge Fund Trend
Increased
By 252.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 20.6%
Last 30 Days ▲ 20.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
484.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
226.17%
Trailing 12-Months
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q3 2025
0:00 / 0:00
PVLA Stock 12 Month Forecast
Average Price Target
$132.55
▲(28.95% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
2.16% Insiders
4.31% Mutual Funds
45.35% Other Institutional Investors
41.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---